Tumor volume growth curves of lymphoma and myeloma xenografts in NOD/SCID mice treated with intratumoral injections of PBS, 10 nmol GRN163, or 10 nmol 227 (missense oligonucleotide). NOD/SCID mice were inoculated with 10 × 106 tumor cells by way of a subcutaneous route. When tumor volumes approached 100 mm3, mice were divided into groups of 5 to 8 animals and were treated with intratumoral PBS (♦), 227 (10 nmol) (•), or GRN163 (10 nmol) (▪) 5 days per week for 3 weeks. Mean tumor volumes ± SE (bars) are shown for the following xenografts: (A) CAG myeloma (TRF, 2.7 kb) (PBS vs GRN163, P ≤ .007 on day 21), (B) Hs602 lymphoma (TRF, 2.7 kb) (PBS vs GRN163, P ≤ .034 on day 21), (C) HT lymphoma (TRF, 11 kb) (PBS vs GRN163, P ≤ .048 on day 22; 227 vs GRN163, P ≤ .36 on day 22). Additional 2-tailed t test analysis on the log (TV) at day 22 in HT xenografts demonstrated PBS versus GRN163 (P ≤ .041) and 227 versus GRN163 (P ≤ .24).
